Background: Systemic candidiasis is caused by Candida invading the bloodstream. The efficacy and safety of echinocandins in monotherapy and combination therapy regimes have not been adequately compared in immunocompromised patients with Candidiasis, and thus this systematic review aims to do so.
Methods: A protocol was prepared a priori. PubMed, Embase and Cochrane Library databases were searched systematically (from inception of each database to September 2022) to identify randomized controlled trials. Two reviewers performed screening, quality assessment of trials, and extracted data independently. Pairwise meta-analysis was performed using random-effects model to compare echinocandin monotherapy versus other antifungals. The primary outcomes of interest were treatment success and treatment-related adverse events.
Results: 547 records (PubMed=310, EMBASE=210 and Cochrane Library=27) were reviewed. Following our screening criteria, six trials involving 177 patients were included. Risk of bias of four included studies had some concerns due to lack of a pre-specified analysis plan. Meta-analysis shows that echinocandin monotherapy does not have significantly higher rates of "treatment success" compared to other classes of antifungals (RR 1.12, 95%CI 0.80-1.56). However, echinocandins appeared to be significantly safer than other forms of antifungal therapy (RR 0.79, 95%CI 0.73-0.86).
Conclusion: Our findings have shown that echinocandin monotherapy (micafungin, caspofungin) given intravenously are just as effective as other antifungals (amphotericin B, itraconazole) in the treatment of systemic candidiasis in immunocompromised patients. There appears to be similar benefits when using echinocandins compared to amphotericin B which has also been used as a broad-spectrum antifungal, while avoiding the severe adverse effects that amphotericin B causes, such as nephrotoxicity.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.mycmed.2023.101362 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Effectiveness and safety of echinocandins combination therapy with the standard of care compared to the standard of care monotherapy for the treatment of invasive aspergillosis infection: a meta-analysis.
Front Pharmacol
December 2024
Department of Pharmacy Practice, College of Clinical Pharmacy, King Faisal University, Al-Ahsa, Saudi Arabia.
Article Synopsis
- This meta-analysis examines the effectiveness and safety of combining echinocandins with standard antifungal treatments for invasive aspergillosis infection (IAI).
- Ten studies with 1,100 patients were reviewed, comparing outcomes like clinical cure rates, mortality, and adverse drug reactions between combination therapy and standard monotherapy.
- Results showed no significant differences in clinical cure rates or mortality between the two approaches, but there indicated a trend towards better outcomes for those receiving echinocandins alongside standard care, with similar safety profiles.
Real-World Antifungal Therapy Patterns Across the Continuum of Care in United States Adults with Invasive Aspergillosis.
J Fungi (Basel)
December 2024
School of Pharmacy, University of Connecticut, 69, North Eagleville Road, Storrs, CT 06269, USA.
Changes to antifungal therapy (AFT) in invasive aspergillosis (IA) may occur due to intolerance, side effects, drug interactions, or lack of response. We describe AFT change patterns in IA patients. This was a US claims data study.
View Article and Find Full Text PDFTreatment of Invasive Pulmonary Aspergillosis and Preventive and Empirical Therapy for Invasive Candidiasis in Adult Pulmonary and Critical Care Patients. An Official American Thoracic Society Clinical Practice Guideline.
Am J Respir Crit Care Med
November 2024
University of Pittsburgh, Pittsburgh, Pennsylvania, United States;
Background: The incidence of invasive fungal infections is increasing in immune-competent and immune-compromised patients. An examination of the recent literature related to the treatment of fungal infections was performed to address two clinical questions. First, in patients with proven or probable invasive pulmonary aspergillosis, should combination therapy with a mold-active triazole plus echinocandin be administered vs.
View Article and Find Full Text PDFAzole Combinations and Multi-Targeting Drugs That Synergistically Inhibit .
J Fungi (Basel)
October 2024
Sir John Walsh Research Institute, University of Otago, Dunedin 9016, New Zealand.
Limited antifungal treatment options and drug resistance require innovative approaches to effectively combat fungal infections. Combination therapy is a promising strategy that addresses these pressing issues by concurrently targeting multiple cellular sites. The drug targets usually selected for combination therapy are from different cellular pathways with the goals of increasing treatment options and reducing development of resistance.
View Article and Find Full Text PDFSuperiority trials in invasive aspergillosis: a harsh reality check with the IA-DUET (HOVON502) trial.
Clin Infect Dis
October 2024
Department of Internal Medicine, Section of Infectious Diseases and department of Medical Microbiology, Erasmus University Medical Center, Rotterdam, The Netherlands.
Article Synopsis
- - The IA-DUET study compared the effectiveness of a combination treatment of azole and echinocandin against azole-only treatment for invasive aspergillosis.
- - Challenges in recruiting participants included high rates of patient ineligibility, the presence of competing studies, and existing guidelines that preferred combination treatment when azole resistance wasn't determined.
- - The low mortality rate linked to invasive aspergillosis indicates that future research may be more effective by using cluster randomization or composite endpoints to improve trial efficiency.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!